This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00080/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00080/identifier/kegg-compound/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00080/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00080/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00080/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/drugbank/patent/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/ontology/sukl/drug/
n25http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00080/identifier/wikipedia/

Statements

Subject Item
n2:DB00080
rdf:type
n5:Drug
n5:description
Daptomycin is a lipopeptide antibiotic that kills susceptible gram positive bacteria by disrupting their membrane potential. It is a naturally-occurring compound found in the soil bacterium <i>Streptomyces roseosporus</i>. Antibiotics are used in the treatment of infections caused by bacteria. They work by killing bacteria or preventing their growth. Daptomycin will not work for colds, flu, or other virus infections. It was approved in September 2003 for the treatment of complicated skin and soft tissue infections. It has a safety profile similar to other agents commonly administered to treat gram-positive infections.
n5:dosage
n23:271B43A5-363D-11E5-9242-09173F13E4C5 n23:271B43A6-363D-11E5-9242-09173F13E4C5 n23:271B43A7-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR: Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992 Feb;36(2):318-25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1318678 # Tally FP, DeBruin MF: Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 2000 Oct;46(4):523-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11020247 # Charles PG, Grayson ML: The dearth of new antibiotic development: why we should be worried and what we can do about it. Med J Aust. 2004 Nov 15;181(10):549-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15540967 # Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17;355(7):653-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16914701 # Lee SY, Fan HW, Kuti JL, Nicolau DP: Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother. 2006 Jul;7(10):1381-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16805723 # http://www.google.com/patents/WO2002059322A2?cl=en #Lexicomp #Dynamed
n5:group
approved investigational
n5:halfLife
Half-life elimination: 8-9 hours (up to 28 hours in renal impairment)
n5:indication
For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms.
n5:manufacturer
n9:271B43A3-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00080 n22:DB00080
dcterms:title
Daptomycin
adms:identifier
n4:Daptomycin n8:PA164768820 n12:D01080 n13:67919-011-01 n15:DB00080 n16:C12013
n5:mechanismOfAction
Daptomycin appears to bind or insert into the outer membrane of gram positive bacteria. The binding and integration of daptomycin into the cell membrane is calcium dependent. Calcium ions cause a conformational change in daptomycin, augmenting its amphipathicity (hydrophilic head group and hydrophobic tail group), leading to incorporation into the cell membrane. This binding causes rapid depolarisation, resulting in a loss of membrane potential leading to inhibition of protein, DNA and RNA synthesis, which results in bacterial cell death. The bactericidal activity of daptomycin is concentration-dependent. There is in vitro evidence of synergy with β-lactam antibiotics.
n5:packager
n9:271B439D-363D-11E5-9242-09173F13E4C5 n9:271B439E-363D-11E5-9242-09173F13E4C5 n9:271B43A1-363D-11E5-9242-09173F13E4C5 n9:271B43A2-363D-11E5-9242-09173F13E4C5 n9:271B439F-363D-11E5-9242-09173F13E4C5 n9:271B43A0-363D-11E5-9242-09173F13E4C5
n5:patent
n6:RE39071 n6:2344318 n6:6468967
n5:routeOfElimination
Daptomycin is excreted primarily by the kidney. In a mass balance study of 5 healthy subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations) and 5.7% of the dose was recovered from feces (collected for up to 9 days) based on total radioactivity. Because renal excretion is the primary route of elimination, dosage adjustment is necessary in patients with severe renal insufficiency (CLCR <30 mL/min)
n5:volumeOfDistribution
* 0.1 L/Kg [healthy adult subjects]
n5:proteinBinding
Daptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The overall mean binding ranged from 90 to 93%.
n5:synthesisReference
Dennis Keith, "Methods for preparing purified daptomycin." U.S. Patent US20030045484, issued March 06, 2003.
n20:hasConcept
n21:M0026638
foaf:page
n18:daptomycin.html n19:cubicin.htm
n5:Molecular-Formula
n14:271B43A9-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n14:271B43A8-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:J01XX09
n5:absorption
Generally exhibits linear and time-independent pharmacokinetics at a dosage of 4–12 mg/kg IV once every 24 hours. Steady-state trough serum concentrations are achieved by the third daily dose.
n5:affectedOrganism
Enteric bacteria and other eubacteria
n5:casRegistryNumber
103060-53-3
n5:clearance
Excreted primarily in the urine as unchanged drug (78%) and in the feces (6%)
n5:containedIn
n7:271B43A4-363D-11E5-9242-09173F13E4C5